Sagimet Shares Drop After Denifanstat Acne Drug Data and Stock Offering Closure
Sagimet Biosciences (SGMT) shares fell approximately 5% on Thursday following the release of 52-week results from a phase 3 open-label extension trial in China for its acne drug denifanstat, conducted by partner Ascletis Pharma. The data did not meet expectations, leading to investor disappointment. In addition to the clinical update, Sagimet announced the completion of a stock offering on Thursday. While such offerings can provide capital, they often raise concerns about dilution and financial strategy among investors. The combined impact of underwhelming trial results and market skepticism over the recent financing led to downward pressure on SGMT's share price.
Tickers: $SGMT
Topics: acne vulgaris Ascletis Pharma denifanstat Sagimet Biosciences